Captisol.

The leading sulfobutylether beta-cyclodextrin (SBECD)

Captisol is a derivatized beta cyclodextrin used in 15 FDA-approved products to date, including VEKLURY® (remdesivir) and KYPROLIS® (carfilzomib) to help solubilize & stabilize difficult to deliver molecules. Made by CyDex Pharmaceuticals (a Ligand Company), Captisol is the leading pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), with an excellent record of safety and consistency.

Captisol has been clinically used in therapeutics across many routes of administration, including parenteral, oral, subcutaneous, ophthalmic, nasal, inhalation, and dermal. Increasingly, companies are exploring the benefits of Captisol in consumer health, supplements, and personal care products.

Learn More About Captisol

Order Captisol Today

Our broad range of products allows you to create the Captisol formulation you need.

Order Now

Consultation for ALL STAGES of Drug Development

Our broad expertise and knowledge offers a wide range of solutions for solubility and stability for your formulation. We are available to partner with you through all the stages of development including:

  • Pre-Formulation/Feasibility Assessment
  • Solubility & Stability Evaluation
  • Formulation Development
  • Regulatory Affairs Consultation
  • Clinical Trial Consultation
Learn More About Our Drug Development Services

Your Drug. Our Cyclodextrin.

Captisol ships quickly and is easy to test in your own research labs with your own compounds. We provide Captisol for research, clinical, and commercial purposes.

Licensing Opportunities

Want to test Captisol for your next product candidate?
Want us to help you test?

CyDex sizes partnerships to fit your specific needs.
Contact us to get started.